Cargando…
Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies
The development and use of combination immunotherapy-based anticancer regimens is at an early but clearly exciting stage. We now demonstrate that the antibody-based co-targeting of multiple immunostimulatory and/or inhibitory pathways can be used safely and effectively in combination with single dos...
Autores principales: | Verbrugge, Inge, Galli, Mara, Smyth, Mark J., Johnstone, Ricky W., Haynes, Nicole M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525626/ https://www.ncbi.nlm.nih.gov/pubmed/23264917 http://dx.doi.org/10.4161/onci.21652 |
Ejemplares similares
-
The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012) -
Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer
por: Morales-Kastresana, Aizea, et al.
Publicado: (2014) -
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
por: Aranda, Fernando, et al.
Publicado: (2014) -
High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies
por: Binder, David C, et al.
Publicado: (2013) -
The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)